Home / Formulary / LL-37

Back to formulary

LORIUM · 5 mg LYOPHILISED VIAL

Third-party tested · COA included with every lot

Recovery ● In stockPrescription required

LL-37

Name: LL-37
Brand: LORIUM
SKU: ll-37
Availability: InStock

Cathelicidin peptide

LL-37 is an advanced, premium endogenous human cathelicidin peptide engineered with powerful dual antimicrobial and deep tissue remodeling properties. By driving direct microbial membrane disruption and optimizing localized host immune signaling, this protocol dramatically accelerates complex dermal regeneration, angiogenesis, and defensive priming at the structural level.

$159 / month · 5 mg

Request through a provider Start intake to prescribe

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. It is dispensed only pursuant to a valid prescription following evaluation by a licensed provider.

Researched effects

Effects observed in the cited literature. Individual results are not guaranteed. Statements have not been evaluated by the FDA.

Advanced Dermal Repair

Accelerates deep tissue recovery and granulation in complex skin areas.

Precision Tissue Regeneration

Drives high-efficiency cellular closure and structural layer growth.

Broad Antimicrobial Activity

Delivers direct, powerful activity against structural bacterial lines.

Membrane Disruption

Exerts strong direct bactericidal and anti-biofilm effects.

Enhanced Angiogenesis

Stimulates structural blood vessel networking to feed developing cells.

Refractory Tissue Support

Demonstrates high clinical efficacy in large or hard-to-heal areas.

Microbial Biofilm Prevention

Inhibits pathogen persistence and defense layers in targeted sites.

Specifications

ClassCathelicidin peptide

CAS number154921-24-1

Molar mass4493.3 g/mol

Available sizes5 mg

AdministrationPremium advanced topical or targeted subcutaneous recovery protocol.

CategoryRecovery

View a sample certificate of analysis →

Clinical references

Grönberg, A., et al. (2014). LL-37 in Enhancing Healing of Hard-to-Heal Ulcers. Wound Repair Regen, 22(5).
Mahlapuu, M., et al. (2021). Evaluation of LL-37 in Dermal Healing: Multicentric Trial. Wound Repair Regen, 29(6).
Miranda, E., et al. (2023). Efficacy of LL-37 in Tissue Closure and Regeneration. Arch Dermatol Res, 315.
Duplantier, A. J., & van Hoek, M. L. (2013). Cathelicidin LL-37 in Infected Wounds. Front Immunol, 4.